Kornimate/medical-research-clean huggingface dataset:
allo hsct for high risk hemoglobinopathies

Conditions: Graft Failure; Sickle Cell Disease; Hemoglobinopathies

Summary: a single center, open label, interventional, phase ii trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (hsct) regimens.


Eligibility criteria:
inclusion criteria: * sickle cell disease (scd) * scd patients with a fully matched sibling donor (msd) irrespective of the frequency or severity of symptoms msd transplant can be considered. parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent * transfusion dependent alpha- or beta- thalassemia * diamond blackfan anemia * other non-malignant hematologic disorders * karnofsky ≥ 60%, lansky play score ≥ 60. patients with lower performance score can be considered based on study team's evaluation. * sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant. exclusion criteria: * pregnant, breastfeeding or intending to become pregnant during the study. persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment * hiv positive * active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted * known allergy to any of the study components * psychiatric illness/social situations that, in the judgement of the enrolling investigator, would limit compliance with study requirements * other illness or a medical issue that, in the judgement of the enrolling investigator, would exclude the patient from participating in this study
tolerability and background fluorescence of the medibeacon transdermal gfr measurement system

Conditions: Acute Kidney Injury

Summary: this study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. in addition, 48-hour tolerability of the sensor and adhesive will be evaluated.

the medibeacon transdermal gfr measurement system investigational is intended to measure the glomerular filtration rate (gfr) in patients with normal or impaired renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent (mb-102) over time. the device utilized in this study is the brilliance device. approximately 1 male and 1 female from each age cohort (18-50 years; 51+ years) and clustered fitzpatrick skin scale groups (i-ii \[light, pale white; white, fair\]; iii-iv \[medium, white to olive; olive, moderate brown\]; and v-vi \[brown, dark brown; black, very dark brown to black\]) will be recruited, for a total of 12 participants. participants will have brilliance device sensors placed on two locations on their skin, which will remain for 48 hours. the sensor location will be prepared through shaving and cleaning (as applicable), placed on the skin via standard single-use adhesive pads, and baseline measurements collected. participants may undergo activities of daily living while measurements are being collected. light pressure and other minor perturbations may be applied to the sensors to evaluate the effect on background fluorescence. adverse events associated with sensor placement (such as skin irritations) will be recorded.

Eligibility criteria:
inclusion criteria: * healthy male and female adults age 18 and older * 2 age cohorts to be recruited: 18 - 50 years of age and 51+ years or older * skin color groups to be recruited in accordance with the fitzpatrick skin scale (i - vi) * participants willing to sign the institutional review board (irb) approved informed consent form prior to the initiation of any study specific procedures. exclusion criteria: * history of skin sensitivity to adhesives (e.g. band-aids, surgical tape) * any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial * significant scarring, tattoos or alterations in pigmentation on the standardized sensor locations that would alter sensor readings versus other areas of the skin

Keywords: glomerular filtration rate
the baerveldt versus clearpath comparison study

Conditions: Glaucoma

Summary: this is a randomized prospective study of post-operative surgical outcomes and complication rates in patients with a baerveldt 350 implant vs the ahmed clearpath implant. each subject will be randomized to the baerveldt group or clearpath group at the time of consent for the study.


Eligibility criteria:
inclusion criteria: * men or women with age at screening ≥ 18 years and ≤ 90 years * inadequately controlled glaucoma * valve-less aqueous shunt as the planned surgical procedure * patients with primary glaucomas or pseudoexfoliation, pigmentary and traumatic glaucoma with a previous failed trabeculectomy or other intraocular surgery included. * primary tubes included * investigators to recruit consecutively all eligible patients from their clinics. * superotemporal or inferonasal placement of the tube * capable and willing to provide consent exclusion criteria: * nlp * unable/unwilling to provide informed consent * unavailable for regular follow up * previous cyclodestructive procedure * prior scleral buckling procedure or other external impediment to supratemporal drainage device implantation * presence of silicone oil * vitreous in the anterior chamber sufficient to require a vitrectomy * uveitic glaucoma * neovascular glaucoma * nanophthalmos * sturge-weber syndrome or other conditions associated with elevated episcleral venous pressure * procedure combined with other surgery * any abnormality other than glaucoma in the study eye that could affect tonometry.

Keywords: baerveldt 350 implant ahmed clearpath implant
relevance of biomarkers for future risk of thromboembolic events in unselected post-myocardial infarction patients

Conditions: Myocardial Infarction

Summary: the study is an open, single center, observational study at the cardiology dept at uppsala university hospital. the number of patients included will be 410. the objectives are to: evaluate biomarkers and change of these related to myocardial infarction, during two years follow-up in an unselected patient population with a recent myocardial infarction. evaluate if an early change of biomarkers can be related to death, new myocardial infarction, and ischemic stroke in the same population after two and five years follow-up.


Eligibility criteria:
inclusion criteria: 1. myocardial infarction diagnosed by dynamic raised troponin i with at least one value above 0.1 µg/l. together with at least one of the criteria; symptoms suggestive for myocardial infarction or development of significant q wave. 2. treated at the department of cardiology, uppsala university hospital. 3. ability to attend the scheduled visits for evaluation procedures. 4. signed informed consent. exclusion criteria: 1. death ≤ 5 days after the myocardial infarction. 2. not belonging to the catchment area of uppsala university hospital. 3. lack of suitability for participation in the trial, for any reason, as judged by the investigator.
improved induction and maintenance immunosuppression in kidney transplantation

Conditions: End-stage Renal Disease

Summary: this 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys. these two potential improvements are each applied in sequence to half of the study patients, creating 4 study arms; the other half receive the standard treatment. the two potential improvements are: 1. administering the immunosuppression induction agent ratg ("rabbit anti-thymocyte globulin") in a single dose at the time of transplantation, instead of in the usual series of 4 smaller doses over 6 days. 2. after 6 months, modifying the maintenance immunosuppression used to prevent rejection by replacing the drug tacrolimus with mycophenolate mofetil (mmf). the two interventions, spaced sequentially six months apart, enable independent analysis of the two treatments so long as it can be shown that there is no synergistic interaction between them.

the two treatment innovations in this study of immunosuppression in kidney transplantation are aimed at making the transplanted kidney function sooner and last longer than is usual with standard immunosuppression regimens, but without increasing the likelihood of rejection. the first innovation, delivering the induction agent ratg in a single large dose rather than as a series of smaller doses over 6-8 days, is expected to produce better graft function right away, possibly by reducing some of the injury to the kidney that accompanies the restoration of blood flow during transplantation ("reperfusion injury"). some evidence has been developed by investigators elsewhere to suggest this will happen. the second innovation, replacing tacrolimus with mmf after 6 months, is intended to eliminate a well-established major cause of ongoing toxic damage to the kidney. while tacrolimus does a good job of preventing rejection, the cost in continuing toxic injury to the kidney is high, leading inevitably to eventual graft failure, the inability of the transplanted kidney to continue filtering the blood and making adequate volumes of high-quality urine.

Eligibility criteria:
inclusion criteria: * primary renal transplant recipient for end-stage renal disease exclusion criteria: * recipient age \ 65 years * previous history of cmv disease * hepatitis b and c recipients * primary disease states that require steroids for immunosuppression * re-transplant with immunological cause of renal or pancreas loss * non heart beating donors * recipient of pediatric en bloc kidneys * recipient with a panel reactive antibody (pra) score \>75% * patients who have received 3 or more prior transplants, excluding pancreas * patients who are past recipients of other solid organ transplants * previous history of bk virus * previous treatment with thymoglobulin * allergy to rabbits * simultaneous kidney/pancreas transplantation

Keywords: induction ratg calcineurin-inhibitor withdrawal
trial on postoperative outcomes according to the number of trocar during laparoscopic appendectomy

Conditions: Appendicitis; Pain; Complications

Summary: appendicitis is the most common benign inflammatory disease that requires an operation. laparoscopic appendectomy using three trocar is generally performed, and reveals good surgical outcomes incluing less pain, early recovey, cosmetic effect et al. however, with using three trocar, there are some problems including pain around trocar insertion sites(three portions), wound infecton and scar at trocar insertion sites. for these reasons, more minimal invasive appendectomy is required, with development of laparoscopic instrument,eventually one port sppectomy is developed. so, the investigators assess post-operative outcomes according to the number of trocar.


Eligibility criteria:
inclusion criteria: * appendicitis (clinical or radilogical diagnosis) * asa \< 4 exclusion criteria: * appendicitis with palpable mass( clinical or radilogical diagnosis) * patient has bleeding tendency * pregnant

Keywords: pain operative times complication time to return for normal life pain using vas score
safety and efficacy of idp-122 in the treatment of participants with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: this study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an investigator's global assessment \[iga\] score of 3 or 4).

this study is a multicenter, double-blind, randomized, parallel-group study designed to assess the safety and efficacy of idp-122 lotion in comparison with its vehicle. to be eligible for the study, participants must be at least 18 years of age and have a clinical diagnosis of moderate to severe psoriasis (defined as an iga score of 3 or 4).

Eligibility criteria:
key inclusion criteria: * male or female, of any race, at least 18 years of age (inclusive). * freely provides both verbal and written informed consent. * has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (bsa) of at least 3%, but no more than 12%. the face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation. * is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study. * has a clinical diagnosis of psoriasis at the baseline visit with an iga score of 3 or 4 (the face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded from this calculation, if psoriasis is present). key exclusion criteria: * has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator. * presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator. * presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator. * is pregnant, nursing an infant, or planning a pregnancy during the study period. * has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the baseline visit or is concurrently participating in another clinical study with an investigational drug or device.
prognostic value of some biochemical markers in breast cancer

Conditions: Breast Cancer Female

Summary: breast cancer is the most common type of cancer in women and first cause of cancer death among them. in egypt it constitutes 33% of female cancer cases and more than22000 new cases diagnosed each year. there are many prognostic factors for breast cancer as tumer size, axillary lymph node status, hormonal receptor status, and tumer markers as ca15-3 and interferon gamma.


Eligibility criteria:
inclusion criteria: * female patients aged more than or equal 18 year diagnosed with breast cancer * metastatic and non-metastatic cancer premenopausal and postmenopausal female positive and negative hormonal receptors and her2 receptor taking any systemic treatment taking radiotherapy or not exclusion criteria: * female patients less than 18 years patients having comorbid disease. patients with double malignancy
clinical and biochemical evaluation of dental and periodontal conditions in children with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis; Gingivitis; Decay, Dental

Summary: aimed to be done in the planned thesis to evaluate the dental and periodontal health of patients with newly diagnosed jia and healthy-periodontal problems with cytokines from saliva and oxidative stress markers non-invasively, and thus, to determine the markers' evaluability in terms of markers in determining the state of inflammation among individuals with and without the disease.

periodontal diseases and inflammatory diseases such as arthritis show similar clinical pathologies such as connective tissue deterioration and bone destruction. they carry the risk of being seen together and the possibility of mutual influence. it is important whether these patients have a difference in cytokine profile from individuals who do not have the disease. in the literature, it has been determined that pro and anti-inflammatory cytokines, which are involved in the pathogenesis of periodontitis, are also involved in the pathogenesis of juvenile idiopathic arthritis (jia). cytokines play an undeniable role in the pathogenesis of both diseases. the cytokine profile in periodontal disease is distinctly similar to that of rheumatoid arthritis (ra). as in ra, the level of pro-inflammatory cytokines such as interleukin-1 beta (il-1β) and tumor necrosis factor-alpha (tnf-α) increase in periodontal disease. again, it is stated that oxidative stress assessment is an important factor in evaluating the development of the disease. saliva evaluation can be made with new oxidative stress markers that can be used in this sense. on the subject of the proposed thesis; it is to determine the profile of dental and periodontal health in a specific group in terms of biochemical and microbiology using different body fluids together with clinical findings and has an interdisciplinary character. aimed to be done in the planned thesis; it was aimed to evaluate the dental and periodontal health of patients with newly diagnosed jia and healthy-periodontal problems with cytokines from saliva and oxidative stress markers non-invasively, and thus, to determine the markers' evaluability in terms of markers in determining the state of inflammation among individuals with and without the disease.

Eligibility criteria:
inclusion criteria: * healty patients exclusion criteria: * used antibiotics within the last 3 months

Keywords: pediatric dentistry periodontal status juvenile idiopathic arthritis
efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Inadequate Glycaemic Control

Summary: this study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus. * cardiovascular disease * uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment exclusion criteria: * patients with type 1 diabetes or diabetes insipidus * patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes * any clinically significant illness, which would compromise the patient's safety and their participation in the study

Keywords: dapagliflozin diabetes cardiovascular disease
evaluation of corrected carotid artery flow time as a predictor of fluid responsiveness in spontaneous breathing patients

Conditions: Brain Tumor

Summary: it is still challenging to assess intravascular volume status in spontaneously breathing patients. recently, the measurement of corrected flow time in carotid artery was introduced as quite useful, simple and noninvasive for the evaluation of circulating blood volume change. the aim of this study is to evaluate whether corrected carotid artery flow time as determined by ultrasonography can be a predictor of fluid responsiveness in spontaneously breathing patients before induction of general anesthesia.


Eligibility criteria:
inclusion criteria: * adult patients (19-80 years of age) who were scheduled to undergo elective neurosurgery for brain tumor exclusion criteria: * bmi \> 35 or \< 15 kg/m2 * the presence of carotid artery stenosis \> 50% * systolic blood pressure \> 160 mmhg * cardiac rhythm other than sinus * intracardiac shunt 6. valvular heart disease * a left ventricular ejection fraction of \< 50% * right ventricular dysfunction 9 * chronic obstructive pulmonary disease * pulmonary hypertension * chronic kidney disease (egfr \< 60 ml/min/1.73m2) * pregnancy
improved operation of low intraocular pressure in phacoemulsification for patients with high myopia complicated with cataract

Conditions: High Myopia; Low Intraocular Pressure

Summary: approximately 60 participants at eye hospital of wenzhou medical university during october,2021 to january 2022 will be enroll in the investigators' study. and dived them randomly into 2 groups:high myopia with axial length between 26 mm and 28 mm and high myopia with axial length more than 28 mm (30 eyes) .


Eligibility criteria:
inclusion criteria: * the patients with high myopia and cataract who plan to receive cataract surgery in our hospital * surgery without complications exclusion criteria: * patients who had other ocular diseases or had undergone internal eye surgery * patients with a history of myopic laser surgery * previous history of eye trauma * previous use of medications/eye drops that may alter iop
pilot trial on immunosuppression modulation to increase sars-cov-2 vaccine response in kidney transplant recipients

Conditions: COVID-19

Summary: mycophenolate has been identified as risk factor for non-response to sars-cov-2 vaccination in kidney transplant recipients. safety and efficacy of temporarily stopping of mycophenolate (or azathioprine) to increase vaccine response has not been established. this is a non-randomized, controlled pilot study including up to 40 kidney transplant recipients not responding to at least three previous sars-cov-2 vaccine doses. mycophenolate or azathioprine will be stopped for two weeks peri-vaccination starting one week before vaccination until one week after vaccination. allocation to mycophenoalte or azathioprine discontinuation arm will be based on an overall risk assessment by the transplant physician and patient preference. patients not stopping mycophenolate or azathioprine will serve as control group.


Eligibility criteria:
inclusion criteria: * patient has received a kidney transplantation * \> 18 years of age * no sars-cov-2 spike protein antibodies four weeks after at least three previous vaccine doses * maintenance immunosuppression with mycophenolate or azathioprine exclusion criteria: * acute illness with fever * prior documented infection with sars-cov-2 * triple anticoagulation therapy * subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s) * subject has known sensitivity or intolerance to any of the products to be administered for the purpose of this study * subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with the study procedures * subject is pregnant or breast feeding * sars-cov-2 spike protein antibodies four weeks after the 3rd last vaccination \> 0.8 bau/ml